Biomm

Biomm Deferred Tax Liabilities

The Deferred Tax Liabilities of Biomm (BIOM3.SA) as of Nov 11, 2026 is 983,000.00 BRL. In the previous year, Deferred Tax Liabilities was 340,000.00 BRL — a change of 189.12% (higher).

Deferred Tax Liabilities

983,000.00BRL

YoY

189.12%

Last updated:

Deferred Tax Liabilities of Biomm is 2024 983,000.00 BRL. Deferred Tax Liabilities of Biomm was 2023 340,000.00 BRL. It decreases by 189.12% higher compared to the previous year.

The Biomm Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2017
22,000.00 BRL
Jan 1, 2018
55,000.00 BRL
Jan 1, 2019
92,000.00 BRL
Jan 1, 2020
155,000.00 BRL
Jan 1, 2021
630,000.00 BRL
Jan 1, 2022
0.00 BRL
Jan 1, 2023
340,000.00 BRL
Jan 1, 2024
983,000.00 BRL
The Biomm Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
983,000.00BRL+189.12%
340,000.00BRL—
0.00BRL-100.00%
630,000.00BRL+306.45%
155,000.00BRL+68.48%
92,000.00BRL+67.27%
55,000.00BRL+150.00%
22,000.00BRL-99.27%
3.01 MBRL-58.84%
7.30 MBRL—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Deferred Tax Liabilities of Biomm is 983,000.00 BRL in 2024.

Deferred Tax Liabilities of Biomm changed from 340,000.00 BRL to 983,000.00 BRL, representing a 189.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Biomm since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's BRL is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Biomm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biomm

All Key Metrics — Biomm